Acceleron Pharma
XLRN
XLRN was delisted on the 19th of November, 2021.
128 hedge funds and large institutions have $1.05B invested in Acceleron Pharma in 2017 Q2 according to their latest regulatory filings, with 13 funds opening new positions, 52 increasing their positions, 32 reducing their positions, and 21 closing their positions.
63% more repeat investments, than reductions
Existing positions increased: 52 | Existing positions reduced: 32
21% more capital invested
Capital invested by funds: $863M → $1.05B (+$184M)
6% less funds holding
Funds holding: 136 → 128 (-8)
25% less funds holding in top 10
Funds holding in top 10: 4 → 3 (-1)
38% less first-time investments, than exits
New positions opened: 13 | Existing positions closed: 21
74% less call options, than puts
Call options by funds: $1.87M | Put options by funds: $7.33M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Westfield Capital Management
Boston,
Massachusetts
|
+$15.5M |
| 2 |
SAM
Sectoral Asset Management
Montreal,
Quebec, Canada
|
+$13.9M |
| 3 |
BlackRock
New York
|
+$9.58M |
| 4 |
PC
Polar Capital
London,
United Kingdom
|
+$9.42M |
| 5 |
Axa
Paris,
France
|
+$9.38M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GTC
Ghost Tree Capital
New York
|
-$8.98M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
-$4.84M |
| 3 |
JP Morgan Chase
New York
|
-$3.31M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
-$3.1M |
| 5 |
PI
Putnam Investments
Boston,
Massachusetts
|
-$3.09M |
XLRN Hedge Fund Activity: Q2 2017 in Review
128 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Acceleron Pharma (XLRN) for Q2 2017, worth a combined $1.05B — up 21% from $863M a quarter earlier.
Sellers outnumbered buyers: 21 funds closed out of XLRN and 13 opened new positions — a net loss of 8 holders — while 32 trimmed existing stakes and 52 added.
The largest buyer was Westfield Capital Management, adding an estimated $15.5M. The largest seller was Ghost Tree Capital, cutting an estimated $8.98M.
- 128 institutional investors held Acceleron Pharma (XLRN) as of Q2 2017, down from 136 in Q1 2017.
- Funds reported $1.05B of Acceleron Pharma stock for Q2 2017, up 21% quarter-over-quarter.
- 13 funds opened new Acceleron Pharma positions in Q2 2017 and 21 closed out, a net change of -8 holders.
- The largest Acceleron Pharma buyer in Q2 2017 was Westfield Capital Management, an estimated $15.5M added.
- The largest Acceleron Pharma seller in Q2 2017 was Ghost Tree Capital, an estimated $8.98M sold.
Based on aggregated 13F filings for Q2 2017.